https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-01 / Expert Rev Vaccines 2014 Jan;13(1):117-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-01 / Expert Rev Vaccines 2014 Jan;13(1):117-302014-01-01 00:00:002021-11-15 16:55:45Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-11-12 / Expert Rev Neurother 2013 Dec;13(12):1395-406
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-11-12 / Expert Rev Neurother 2013 Dec;13(12):1395-4062013-11-12 00:00:002021-11-15 13:32:44Myeloid-derived suppressor cells in glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-11-06 / Oncoimmunology 2013 Dec;2(12):e27059
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-11-06 / Oncoimmunology 2013 Dec;2(12):e270592013-11-06 00:00:002021-11-15 13:33:23Dendritic cell-based immunotherapy in ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-10-01 / Immunotherapy 2013 Oct;5(10):1043-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-10-01 / Immunotherapy 2013 Oct;5(10):1043-62013-10-01 00:00:002021-11-15 14:42:34Immunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-09-01 / Anticancer Res. 2013 Sep;33(9):3855-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-09-01 / Anticancer Res. 2013 Sep;33(9):3855-92013-09-01 00:00:002021-11-15 14:43:00Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-08-14 / Cancers (Basel) 2013 Aug;5(3):1020-48
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-08-14 / Cancers (Basel) 2013 Aug;5(3):1020-482013-08-14 00:00:002021-11-15 14:43:30Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-07-02 / Biology (Basel) 2013 Jul;2(3):936-75
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-07-02 / Biology (Basel) 2013 Jul;2(3):936-752013-07-02 00:00:002021-11-15 16:56:11Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-02-01 / BioDrugs 2013 Feb;27(1):35-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-02-01 / BioDrugs 2013 Feb;27(1):35-532013-02-01 00:00:002021-11-15 16:56:59Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-04-22 / Cancer Immunol. Immunother. 2012 Nov;61(11):2033-44
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-04-22 / Cancer Immunol. Immunother. 2012 Nov;61(11):2033-442012-04-22 00:00:002021-11-15 14:43:58Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-01-01 / Methods Mol. Biol. 2012;797:177-204
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-01-01 / Methods Mol. Biol. 2012;797:177-2042012-01-01 00:00:002021-11-15 16:57:22Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation